Health-care billing tech provider Cedar Cares raises $200M led by Tiger Global at a $3.2B valuation, more than four times its value in a funding round last year
Context & Ripple Effects
Cedar has been on a steady fundraising ladder: a $36M Series B in 2018 followed by an $102M Series C led by a16z in mid-2020 brought total funding to $157M. Today's $200M round at $3.2B — more than four times its valuation just one year earlier — marks the step-change.
The round fits Tiger Global's 2021 cadence exactly: the fund led Hinge Health's $400M raise at $6.2B, double its January mark, and had already tripled Vast Data's valuation to $3.7B within a year. Cedar is the same playbook applied to patient billing.
First-order effects
- Cedar gains $200M and a $3.2B valuation to push data-driven patient billing deeper into health systems, with Tiger Global replacing a16z as lead investor on the cap table.
- The 4x jump in twelve months resets the pricing benchmark for every health-care revenue-cycle startup raising next.
Second-order effects
- Rivals consolidating adjacent ground — such as Tebra, formed from the Kareo-PatientPop merger — now face a competitor with roughly twice their valuation tier and fresh capital to bundle or undercut on the provider-billing relationship.
- Other portfolio-style health-tech companies can shop Tiger-led marks to their own investors, accelerating compressed round-to-round timelines across digital health.
Third-order effects
- If crossover funds keep re-marking companies upward within months, private valuations decouple from fundamentals — and the same fund's later markdowns (a 45% cut at Superhuman, 72% at DuckDuckGo per related reporting) show how quickly that cycle can reverse for late entrants.
- Patient-facing financial infrastructure in health care consolidates around a few heavily capitalized platforms, squeezing independent billing vendors into acquisition paths or niche specialization.
The trend: Crossover funds led by Tiger Global are compressing health-tech fundraising cycles, doubling valuations between rounds and setting up a sharp repricing risk when the cycle turns.